Navigation Links
Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
Date:4/13/2009

via(TM) in Asia.

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp. ("Raptor") is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it believes it can have the greatest potential impact. Raptor currently has product candidates in clinical development to treat nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease ("Huntington's"), and aldehyde dehydrogenase ("ALDH2") deficiency.

Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: that Dr. Rioux' successful clinical and regulatory track record will benefit and / or advance the Company's clinical-stage programs through the clinic and into the market; that the Company's pipeline could address serious unmet medical needs; that the Company will be successful in initiating and / or completing its planned clinical trials; that the Company will successfully file an NDA in 2010; that clinical results from planned or ongoing clinical trials will be available as planned or that th
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
2. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
3. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
4. Raptor Pharmaceuticals Provides Update on Targeting Platforms
5. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
6. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
7. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
8. Raptor Pharmaceuticals Provides Update of Product Programs
9. Strativa Pharmaceuticals Provides Product Pipeline Update
10. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
11. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , August 28, 2014 ... Market Research "Radiofrequency Identification (RFID) Market (Tags, Readers, Middleware, ... Growth, Trends and Forecast, 2014 - 2020" the global ... billion in 2013 and is expected to grow at ... reach an estimated value of USD 5.3 billion in ...
(Date:8/28/2014)... 28, 2014   Venaxis, Inc.  (Nasdaq:  APPY), an ... FDA clearance for and commercializing its CE Marked ... in identifying children, adolescent, and young adult patients in ... appendicitis, today announced it will present at three upcoming ... Annual Global Investment Conference being held in ...
(Date:8/28/2014)... 2014 Telik, Inc. (OTCQB: TELK), a ... with MabVax Therapeutics, Inc. on July 8, 2014, ... to the development of its lead antibody program ... the Company,s internally developed antibody discovery platform.  These ... antibody based therapeutic and diagnostic products based on ...
Breaking Medicine Technology:Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4
... traits contribute to risk, of skin cancer; findings will ... May 18 In two papers published,today, deCODE scientists ... the company,s recent findings in the genetics of pigmentation,traits ... of these,common variants also confer risk of two types ...
... Annual Meeting Will Further Demonstrate, the Strength ... CAMBRIDGE, Mass., May 16 Millennium Pharmaceuticals,The Takeda Oncology ... are scheduled to be featured at the 2008 American ... May 30 -,June 3, 2008. The data will highlight ...
Cached Medicine Technology:deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 2deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 3deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8
(Date:8/28/2014)... August 28, 2014 Save On ... tech accelerator program in Tampa. Healthbox Florida has ... healthcare companies grow and achieve their goals. , ... 16th, at their launch event at the Mahaffey Theater ... , Co-founder Matt Schneider commented on the Save On ...
(Date:8/28/2014)... Commercial growers all over the continent are waitlisted to ... lights, which perform on par with 1000w HPS at 65% ... needs no cooling equipment and does not overheat the space, ... in that they never need bulbs changed, the internal ROI ... , For many indoor growers, cooler room temperatures also has ...
(Date:8/28/2014)... candidate Ebola vaccine could be given to healthy volunteers ... as September, as part of an series of safety ... that has killed more than 1,400 people in the ... this candidate vaccine, being co-developed by the US National ... accelerated with funding from an international consortium in response ...
(Date:8/28/2014)... repairing nerves with adhesives, most researchers place glue directly ... fix the nerve ends well and allows glue to ... cylindrical. However, it is difficult to insert the nerve ... and there is frictional resistance. Xiangdang Liang and co-workers ... special conduit for the adhesive technique and defined the ...
(Date:8/28/2014)... (Aug. 28, 2014) A subset of patients with ... treated with irinotecan-based therapy, according to a new study ... official journal of the American Gastroenterological Association. , When ... leucovorin adjuvant irinotecan therapy improved overall survival rates ... CIMP is seen in about 10 to 20 percent ...
Breaking Medicine News(10 mins):Health News:Save On Medical Accepted Into Healthbox Accelerator Program 2Health News:New Kind K5 Series LED Grow Lights Pave Way for Future of Indoor Gardening 2Health News:Ebola vaccine trials fast-tracked by international consortium 2Health News:Ebola vaccine trials fast-tracked by international consortium 3Health News:Ebola vaccine trials fast-tracked by international consortium 4Health News:Drug shows promise for subset of stage III colon cancer patients 2
... using small impulses of electricity. This innovative device is ... // (TENS) technology, which has long been used by ... pain. ,The device comes in the form of a ... in the air from the snoring sound. ,Sensors ...
... scientists have developed a test that can detect the Hepatitis ... by Arieh Yaari of Soroka University Medical Centre // ... people without kidney functions whose blood must be passed through ... SciDev Net. ,Such patients have a high incidence of ...
... British Cardiac Society, the British Hypertension Society, Diabetes ... // and the Stroke Association have collaboratively ... attacks, stroke and hardening of leg arteries. The ... of developing heart attacks by properly maintaining one’s ...
... cannot be cured by taking medications reports a study ... review of eight // clinical trials that complementary and ... occur after alcohol consumption. Some of the common hangover ... diarrhea, dizziness, fatigue, depressed, poor memory. ,Though, ...
... Health experts in the United States fear that if the deadly ... risk since they are vulnerable // to the H5N1 virus. ... 70 lives in Asia and has appeared in parts of Europe ... slaughtered in an effort to contain the virus. However, experts fear ...
... study conducted at Oregon Health & Science University and ... that a perfect molecular mixture present in male-emitted pheromone ... and increased aggression) dictates the sexual behavior of other ... interest. ,The researchers argue that release of ...
Cached Medicine News:Health News:The Chemistry Of Sexual Attraction Between Male And Female Elephants 2
The EZY Close post op shoe's flap-on-flap closure provides a secure fit and can accommodate even the bulkiest of dressing. Perfect for older patients with limited hand dexterity....
This popular post op shoe provides quality care at an outstanding value. The semi-rigid outsole provides stability and minimizes flexure....
... who experience severe plantar fasciitis pain, the ... fibrous tissue that can occur after rest ... in the morning. The continuous tension and ... plantar fasciitis and helps stretch the Achilles ...
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
Medicine Products: